Food Bioscience, Год журнала: 2023, Номер 57, С. 103466 - 103466
Опубликована: Дек. 17, 2023
Язык: Английский
Food Bioscience, Год журнала: 2023, Номер 57, С. 103466 - 103466
Опубликована: Дек. 17, 2023
Язык: Английский
Cancers, Год журнала: 2023, Номер 15(2), С. 485 - 485
Опубликована: Янв. 12, 2023
Obesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but also risk factor for the development of mortality related to subgroup cancer. This review focuses on epidemiology, relationship between obesity recurrence cancer management obesity.
Язык: Английский
Процитировано
331Nutrients, Год журнала: 2024, Номер 16(6), С. 800 - 800
Опубликована: Март 11, 2024
Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence increased over years. A potential strategy to counter growing spread various forms cancer is adoption prevention strategies, in particular, use healthy lifestyles, such maintaining weight, following diet; being physically active; avoiding smoking, alcohol consumption, sun exposure; vitamin D supplementation. These modifiable risk factors are associated with this disease, contributing development, progression, severity. This review evaluates relationship between potentially overall specifically breast, colorectal, prostate cancer, highlights updated recommendations on prevention. The results numerous clinical epidemiological studies clearly show influence lifestyles development cancer. An incorrect diet, composed mainly saturated fats processed products, resulting body combined physical inactivity, induced an increase all three types under study. Given importance adopting correct prevent global institutions should develop strategies environments that encourage individuals adopt regular behaviors.
Язык: Английский
Процитировано
65Journal of clinical lipidology, Год журнала: 2024, Номер 18(3), С. e320 - e350
Опубликована: Апрель 24, 2024
BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.
Язык: Английский
Процитировано
27Obesity Pillars, Год журнала: 2024, Номер 10, С. 100108 - 100108
Опубликована: Март 12, 2024
This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.
Язык: Английский
Процитировано
19Current Gastroenterology Reports, Год журнала: 2022, Номер 25(2), С. 31 - 44
Опубликована: Дек. 5, 2022
Язык: Английский
Процитировано
50Obesity Pillars, Год журнала: 2023, Номер 5, С. 100056 - 100056
Опубликована: Янв. 28, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.
Язык: Английский
Процитировано
32Reviews in Endocrine and Metabolic Disorders, Год журнала: 2023, Номер 24(4), С. 611 - 631
Опубликована: Март 31, 2023
Язык: Английский
Процитировано
28Journal of Nutrition and Metabolism, Год журнала: 2024, Номер 2024(1)
Опубликована: Янв. 1, 2024
Lycopene is a naturally occurring carotenoid predominantly found in tomatoes and tomato‐based products. Like other phytochemicals, it exhibits health beneficial biological activities that can be exploited when used as dietary supplement. In vitro vivo , lycopene has been demonstrated to mitigate oxidative stress‐induced metabolic dysfunctions diseases including inflammation, obesity, diabetes mellitus. shown alleviate affect the bone, eye, kidney, liver, lungs, heart, nervous system. This review presents state of art regarding lycopene’s benefits its potential applications system delivery. Furthermore, protective effects against toxins, safety use, possible toxicity are explored.
Язык: Английский
Процитировано
13BioNanoScience, Год журнала: 2024, Номер 14(4), С. 4108 - 4130
Опубликована: Апрель 11, 2024
Язык: Английский
Процитировано
7Obesity Pillars, Год журнала: 2022, Номер 3, С. 100034 - 100034
Опубликована: Авг. 10, 2022
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. The scientific support for this CPS based upon published citations, clinical perspectives OMA authors, and peer review by the leadership. discusses oversimplifications, utilizing referenced publications such as integrative use other CPSs help explain applicable physiology/pathophysiology. on oversimplifications one a series designed assist in care patients with disease obesity. Knowledge underlying science may medicine clinician improve
Язык: Английский
Процитировано
26